| 吴燕飞,张腾.逐瘀活血汤联合依达拉奉治疗脑梗死患者疗效观察及对神经功能、活动能力的影响[J].浙江中西医结合杂志,2025,35(12): |
| 逐瘀活血汤联合依达拉奉治疗脑梗死患者疗效观察及对神经功能、活动能力的影响 |
| Observation on the therapeutic effect of Zhuyu Huoxue decoction combined with edaravone on patients with cerebral infarction in the recovery period and its impacts on neurological function and activity ability |
| 投稿时间：2024-12-17 修订日期：2025-05-13 |
| DOI： |
| 中文关键词: 逐瘀活血汤 依达拉奉 脑梗死 神经功能 活动能力 |
| 英文关键词:Zhuyu Huoxue decoction Edaravone Cerebral infarction Neurological function Activity ability |
| 基金项目:2022年浙江省卫生健康科技计划(2022KY1073) |
|
| 摘要点击次数: 103 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨逐瘀活血汤联合依达拉奉治疗脑梗死(CI)患者疗效及对神经功能、活动能力的影响。方法：选取于本院治疗的108例CI患者,采用随机数字表法分为中药汤剂组和依达拉奉组,每组54例。依达拉奉组采用依达拉奉注射液静脉滴注,中药汤剂组口服依达拉奉及逐瘀活血汤治疗。比较两组临床疗效、中医证候积分、相关神经功能指标、活动能力水平及不良反应发生情况。结果：依达拉奉组总有效率为77.78%,中药汤剂组为96.30%,组间比较差异显著(P＜0.05)；两组治疗后各项中医症状评分均明显降低(P＜0.05),且中药汤剂组较依达拉奉组降低更明显(P＜0.05)；两组美国国立卫生研究院卒中量表(NIHSS)评分均有所下降,且中药汤剂组下降幅度显著高于依达拉奉组(P<0.05)；两组Barthel评分均有所升高,且中药汤剂组上升幅度显著高于依达拉奉组(P<0.05)；依达拉奉组、中药汤剂组总不良反应发生率分别为7.41%、1.85%,组间比较无明显差异(P＞0.05)。结论：逐瘀活血汤联合依达拉奉治疗CI患者,能产生较好的临床疗效,有效改善患者中医证候,恢复神经功能及活动能力,安全性较高。 |
| 英文摘要: |
| Objective: To explore the therapeutic effect of Zhuyu Huoxue decoction combined with Edaravone on cerebral infarction (CI) patients and its impacts on neurological function and activity ability. Methods: A total of 108 CI patients treated in our hospital were randomly separated into a decoction group and an edaravone group using a random number table method, with 54 cases in each group. The edaravone group was treated with intravenous infusion of edaravone injection, while the decoction group was treated with oral administration of edaravone and Zhuyu Huoxue decoction. The Clinical efficacy, traditional Chinese medicine syndrome score, related neurological function index, activity level and adverse reactions were compared between the two groups. Results: The total effective rate of the edaravone group was 77.78%, while that of the decoction group was 96.30%, with significant difference (P<0.05). After treatment, the scores of various traditional Chinese medicine symptoms in both groups were greatly reduced (P<0.05), and the decrease in the decoction group was more significant than that in the edaravone group (P<0.05). The National Institutes of Health Stroke Scale (NIHSS) scores in both groups showed a decrease, and the decrease in the decoction group was significantly larger than that in the edaravone group (P<0.05). The Barthel score in both groups increased, and the increase in the decoction group was greatly larger than that in the edaravone group (P<0.05). The total incidence of adverse reactions in the edaravone group and the decoction group was 7.41% and 1.85%, respectively, with no significant difference (P>0.05). Conclusion: The combination of Zhuyu Huoxue decoction and edaravone can produce good clinical efficacy in treating CI patients, effectively improve traditional Chinese medicine syndromes, restore neurological function and activity ability, and have high safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
